Skin-Selective JAK Coupling Compounds for Controlled Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing JAK inhibitors require high doses or have side effects, and systemic administration often fails to circumvent the contradiction between efficacy and side effects, necessitating a need for skin-selective administration to enhance efficacy while reducing systemic toxicity.
Innovation Solution
Structural optimization of known JAK inhibitors through coupling with specific linkers and small molecules to enhance transdermal penetration, utilizing a chemical bond that is unstable in human skin to release effective ingredients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic administration of JAK inhibitors is used to achieve therapeutic effect, then efficacy is improved, but systemic side effects increase
Solution Approach 1:
The patent applies local quality by designing a prodrug compound that is specifically activated in skin tissue. The compound structure includes a skin-selective release mechanism where the drug is converted to its active form only in the skin, providing localized therapeutic action while avoiding systemic exposure and associated side effects.
Solution Approach 2:
The patent uses an ester linkage as an intermediary mechanism between the inactive prodrug form and the active JAK inhibitor. This ester bond serves as a chemical mediator that is stable during systemic circulation but is selectively hydrolyzed by esterases in skin tissue, enabling controlled local activation of the drug.
2Reliability
If high doses of JAK inhibitors are administered to overcome side effects, then therapeutic effect is improved, but toxicity increases
Solution Approach 1:
The prodrug design enables high local concentration of the active drug in skin tissue without requiring high systemic doses. The skin-selective activation mechanism ensures that therapeutic levels are achieved locally while maintaining low systemic exposure, thereby improving the therapeutic index and reducing toxicity.
3Ease of operation
If transdermal penetration is enhanced by structural optimization, then skin-selective administration is improved, but compound complexity increases
Solution Approach 1:
The patent creates a composite prodrug molecule by combining the JAK inhibitor core structure with a skin-selective ester moiety. This composite structure leverages the properties of both components: the pharmacological activity of the JAK inhibitor and the skin-targeting capability of the ester group, achieving enhanced transdermal penetration through a relatively simple structural modification.
4Loss of time
If known JAK inhibitors are optimized structurally rather than developing new compounds, then development cycle is shortened, but transdermal penetration may be limited
Solution Approach 1:
The patent applies preliminary action by pre-modifying known JAK inhibitors with skin-selective ester groups before administration. This preliminary structural optimization allows the use of already-characterized active ingredients while adding the desired transdermal penetration capability, thus shortening the development cycle compared to creating entirely new compounds.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized compounds achieve increased transdermal potential and controlled drug release, enhancing effectiveness for skin diseases while minimizing systemic side effects.
Implementation Method 1
The chemical bond between the linker and the JAK inhibitor is unstable in the human skin, leading to hydrolysis and release of effective ingredients
Data Source
AI summary
An anti-inflammatory drug compound, and a preparation method therefor and the use thereof. The structural formula of the compound is A-Y—B, wherein A is a group after dehydrogenation of an amine compound having JAK inhibitory activity, Y is a direct connection or —(CH2)-O— or, and B is a group formed by means of dehydroxylation of a carboxy-containing carboxylic acid compound B1, or a group formed by means of dehydrogenation of a hydroxy-containing compound B2. The compound has the special effects of having a strong transdermal property, controlled drug release, high efficacy, etc.